Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

What is the effect of statins on amputations, and survival in peripheral vascular disease?

indicación de tratamiento con estatinasThe prevalence of peripheral arterial disease is between 15% and 20% of patients older than 65 years and its severity is greatly underestimated. In fact, annual mortality is higher in patients with peripheral arterial disease (8.2%) than in those after acute myocardial infarction (6.3%). Despite the above, medical advice and efforts to modify risk factors are far below those observed in those with coronary heart disease or stroke.

Definitely we are doing something wrong…


Read also: Statin Pre-Treatment for the Prevention of Peri-Procedural Events in Carotid Artery Stenting.


The guidelines for the indication of statins in peripheral vascular disease, are largely extrapolated from the data of coronary disease or stroke. Therefore, the objective of this study was to determine the effect of the intensity of statin treatment in this specific population over hard end points such as amputation and mortality.

An intensive treatment with statins was compared with a moderate/mild treatment and antiplatelet therapy, but without statins.

A cohort of 155,647 patients with peripheral vascular disease was included, of which more than a quarter (28%) were not receiving statins.


Read also: When to Indicate Statin Therapy.


The use of intensive treatment was only 6.4%, compared to 18.4% of those with a diagnosis of coronary or carotid disease.

The incidence of amputation and death, decreased significantly with any dose of statins versus antiplatelet therapy alone. But this reduction was also increasing as the intensity of the treatment increased (intensive treatment amputation HR 0.67, CI 95% 0.61 to 0.74 versus mild/moderate treatment; amputation HR 0.81 0.75 to 0.86 and intensive treatment mortality HR 0.74, CI 95% 0.70 to 0.77 versus mild/moderate mortality HR 0.83 0.81 to 0.86 with p<0.001 for all comparisons).


Read also: Early Endarterectomy Seems Superior to Carotid Stenting in Symptomatic Patients.


The association between the intensity of statin treatment and the reduction of amputations and death, remained significant after adjustment with propensity score, sensitivity analysis and subgroup analysis.

Conclusion

Statins, particularly aggressive schemes, are underutilized in peripheral vascular disease. This is the first population study that shows that the intensity of statin treatment at the time of diagnosis of peripheral vascular disease is associated with a reduction in amputations and mortality.

Original title: Statins Have a Dose-Dependent Effect on Amputation and Survival in Peripheral Artery Disease Patients.Reference: Shipra Arya et al. Circulation. 2018 Jan 12. Epub ahead of print.

Reference: Shipra Arya et al. Circulation. 2018 Jan 12. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...